Anti-CD20 antibody induces the improvement of cytokine-induced killer cell activity via the STAT and MAPK/ERK signaling pathways.
about
Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity.Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen
P2860
Anti-CD20 antibody induces the improvement of cytokine-induced killer cell activity via the STAT and MAPK/ERK signaling pathways.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Anti-CD20 antibody induces the ...... d MAPK/ERK signaling pathways.
@en
Anti-CD20 antibody induces the ...... d MAPK/ERK signaling pathways.
@nl
type
label
Anti-CD20 antibody induces the ...... d MAPK/ERK signaling pathways.
@en
Anti-CD20 antibody induces the ...... d MAPK/ERK signaling pathways.
@nl
prefLabel
Anti-CD20 antibody induces the ...... d MAPK/ERK signaling pathways.
@en
Anti-CD20 antibody induces the ...... d MAPK/ERK signaling pathways.
@nl
P2093
P2860
P356
P1476
Anti-CD20 antibody induces the ...... d MAPK/ERK signaling pathways.
@en
P2093
P2860
P304
P356
10.3892/ETM.2015.2264
P577
2015-02-05T00:00:00Z